

Orticumab

Cat. No.:	HY-P99793
CAS No.:	1314241-10-5
Target:	LDLR
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement [1][2].								
In Vitro	Orticumab (10 µg/mL; 24 h) increases CD14 ⁺ ICOS-L ⁺ population in oxLDL-stimulated PBMC's in vitro ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	Orticumab (10 mg/mouse; i.p.; once weekly for 3 weeks) reduces atherosclerosis in the aortic arch, decreases the CD68-macrophage subvalvular plaque staining ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>B6.lpr.ApoE^{-/-} mice (18-week-old) fed with high-fat diet (HFD)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>10 mg/mouse</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; once weekly for 3 weeks</td> </tr> <tr> <td>Result:</td> <td>Reduced atherosclerosis in the aortic arch by 42.8%, decreased the CD68-macrophage subvalvular plaque staining by 30.5%.</td> </tr> </table>	Animal Model:	B6.lpr.ApoE ^{-/-} mice (18-week-old) fed with high-fat diet (HFD) ^[1]	Dosage:	10 mg/mouse	Administration:	Intraperitoneal injection; once weekly for 3 weeks	Result:	Reduced atherosclerosis in the aortic arch by 42.8%, decreased the CD68-macrophage subvalvular plaque staining by 30.5%.
Animal Model:	B6.lpr.ApoE ^{-/-} mice (18-week-old) fed with high-fat diet (HFD) ^[1]								
Dosage:	10 mg/mouse								
Administration:	Intraperitoneal injection; once weekly for 3 weeks								
Result:	Reduced atherosclerosis in the aortic arch by 42.8%, decreased the CD68-macrophage subvalvular plaque staining by 30.5%.								

REFERENCES

[1]. Yao Mattisson I, et al. Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus. *Vascul Pharmacol.* 2021 Oct;140:106863.

[2]. Liang BC, et al. Compositions and methods with anti-ApoB100 antibody or fragment for treatment of psoriasis: World Intellectual Property Organization, WO2019232070 A1. 2019-12-05.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA